Gonadotropin-releasing hormone antagonist (GnRH-ant) protocols are widely used due to their advantages of short stimulation time, low costs, and a lower incidence of ovarian hyperstimulation syndrome (OHSS) (1–3). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.